<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00256451</url>
  </required_header>
  <id_info>
    <org_study_id>803866</org_study_id>
    <nct_id>NCT00256451</nct_id>
  </id_info>
  <brief_title>Endophenotype for Alcohol Misuse in Healthy Minority Populations</brief_title>
  <acronym>DEFINE</acronym>
  <official_title>Defining an Endophenotype for Alcohol Misuse: A Focus On Minority Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to understand the relationship between what an individual
      inherited from their family (genetics), how they respond and feel after drinking alcohol, and
      how they respond to pre-treatment with naltrexone, a medication that blocks some of the
      effects of alcohol and is approved for the treatment of alcoholism. The investigators are
      conducting this study on those of African descent because there is almost no research focused
      on this group and the association with genetics. The investigators seek to enroll 40 people
      in the study. Participation will consist of 4 different alcohol challenge sessions in a cross
      over design. Each session will be separated by at least 10 days. In total, there will be four
      challenge sessions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to test the degree to which specific genetic markers alter the relationship
      between subjective and objective measures of response to alcohol ingestion among non-alcohol
      dependent adults of African descent in a laboratory environment. To meet this aim,
      non-alcohol dependent adults of African descent will be recruited for participation to meet
      the N-goal of 40 trial completers. After consenting, genotyping, and completing the baseline
      assessment, they will participate in four separate alcohol challenge sessions separated by at
      least 10 days. During each of the sessions, subjects will be administered alcohol or sham
      drinking challenge sessions and pretreatment with either naltrexone (50 mg/day) or placebo in
      a double-blind fashion. The order of the four sessions will be randomly assigned. During each
      session, physiological and subjective response will be measured. We will select subjects to
      assure equal number of participants with at least one copy of the Val6 allele compared to
      those homozygous for the Ala6 allele.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biphasic Alcohol Effects Scale - Stimulation</measure>
    <time_frame>During challenge sessions</time_frame>
    <description>Change from baseline to peak for the feeling of stimulation after alcohol ingestion
Biphasic Alcohol Effects Scale - Stimulation: sum of 7 items each rated on 11 point Likert scale (0=not at all, 10=extremely). Minimum=0, maximum=70, higher scores=worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Profile of Mood States - Vigor</measure>
    <time_frame>during the challenge session</time_frame>
    <description>Change from baseline to peak for the amount of Vigor experienced after alcohol ingestion
Profile of Mood States - Vigor: sum of 6 items each rated on 5 point Likert scale (0: not at all, 4: extremely). Minimum=0, maximum=20, higher scores = better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective High From Alcohol Scale</measure>
    <time_frame>during the alcohol ingestion</time_frame>
    <description>Change from baseline to peak for the self reported feeling of being high after drinking
Subjective High from Alcohol Scale: sum of 15 items rated on a 8 point Likert scale (0-7). Minimum=0, maximum=105, higher scores=worse outcomes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biphasic Alcohol Effects Scale - Sedation</measure>
    <time_frame>During the challenge session</time_frame>
    <description>Change from baseline to peak of the amount of sedation post ingestion of alcohol
Biphasic alcohol effects scale - Sedation: sum of 7 items rated on 11 point Likert scale (0=not at all, 10=extremely). Minimum=0, maximum=70, lower scores=worse outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Mood States - Fatigue Scale</measure>
    <time_frame>During the challenge session</time_frame>
    <description>Change from baseline to peak of the degree of fatigue experienced after alcohol ingestion
Profile of Mood States - Fatigue scale: sum of 5 items rated on 5-point Likert scale (0=not at all, 4=extremely). Minimum=0, maximum=20, higher score=worse outcome</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ALC and NAL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>alcohol and active naltrexone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham ALC and NAL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&quot;sham&quot; alcohol and active naltrexone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo pill and ALC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo naltrexone and alcohol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo pill and Sham ALC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo naltrexone and placebo (non-alcoholic) alcohol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>50 mg/day for two days prior to the alcohol challenge session</description>
    <arm_group_label>ALC and NAL</arm_group_label>
    <arm_group_label>Sham ALC and NAL</arm_group_label>
    <other_name>ReVia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo pills</description>
    <arm_group_label>placebo pill and ALC</arm_group_label>
    <arm_group_label>placebo pill and Sham ALC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>alcohol</intervention_name>
    <description>190 proof alcohol prepared to 11% volume mixed with fruit juice.</description>
    <arm_group_label>ALC and NAL</arm_group_label>
    <arm_group_label>placebo pill and ALC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham alcohol</intervention_name>
    <description>non-alcoholic placebo alcohol</description>
    <arm_group_label>Sham ALC and NAL</arm_group_label>
    <arm_group_label>placebo pill and Sham ALC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female and 21 years of age or older

          -  Drinks less than an average of 21 drinks/week with no more than 2 binge episodes per
             week

          -  Of African descent by self report

        Exclusion Criteria:

          -  Meets DSM-IV criteria for lifetime dependence on any substance other than nicotine

          -  Subjects who test positive on the urine drug screen for opioids, cocaine, marijuana,
             or amphetamine at the screening visit

          -  Subjects who meet current or lifetime DSM-IV criteria for bipolar affective disorder,
             schizophrenia, or any psychotic disorder

          -  The presence of unstable or serious medical illness; including history of stroke,
             seizure disorder, severe liver disease (AST or ALT &gt; 5X normal at the time of
             randomization), or unstable cardiac disease

          -  Needs treatment with any psychotropic medication (antidepressant, antipsychotic,
             benzodiazepine, or mood stabilizing medication)

          -  Pre-menopausal female subjects who are pregnant, nursing, or not using a reliable
             method of contraception

          -  Insulin-dependent diabetes

          -  Any medical or psychological condition that could jeopardize the subject's safe
             participation in the trial as determined by the PI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Oslin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania Treatment Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 17, 2005</study_first_submitted>
  <study_first_submitted_qc>November 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <results_first_submitted>September 14, 2017</results_first_submitted>
  <results_first_submitted_qc>August 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2019</results_first_posted>
  <last_update_submitted>August 16, 2019</last_update_submitted>
  <last_update_submitted_qc>August 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>David Oslin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Naltrexone</keyword>
  <keyword>Alcohol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were only randomized to 4 sequences and not to all 12 possible sequences.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ntx-Alc; Placebo-Sham; Ntx-Sham; Placebo-Alc</title>
          <description>Session1: alcohol and active naltrexone Naltrexone: 50 mg/day for two days prior to the alcohol challenge session alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice.
Session2:placebo naltrexone and placebo (non-alcoholic) alcohol placebo: placebo pills Sham alcohol: non-alcoholic placebo alcohol Session3: &quot;sham&quot; alcohol and active naltrexone Naltrexone: 50 mg/day for two days prior to the alcohol challenge session Sham alcohol: non-alcoholic placebo alcohol Session4: placebo naltrexone and alcohol placebo: placebo pills alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice.</description>
        </group>
        <group group_id="P2">
          <title>Ntx-Sham; Ntx-Alc; Placebo-Alc; Placebo-Sham</title>
          <description>Session1: &quot;sham&quot; alcohol and active naltrexone Naltrexone: 50 mg/day for two days prior to the alcohol challenge session Sham alcohol: non-alcoholic placebo alcohol Session2: alcohol and active naltrexone Naltrexone: 50 mg/day for two days prior to the alcohol challenge session alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice.
Session3: placebo naltrexone and alcohol placebo: placebo pills alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice.
Session4: placebo naltrexone and placebo (non-alcoholic) alcohol placebo: placebo pills Sham alcohol: non-alcoholic placebo alcohol</description>
        </group>
        <group group_id="P3">
          <title>Placebo-Alc; Ntx-Sham; Placebo-Sham; Ntx-Alc</title>
          <description>Session1: placebo naltrexone and alcohol placebo: placebo pills alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice.
Session2: &quot;sham&quot; alcohol and active naltrexone Naltrexone: 50 mg/day for two days prior to the alcohol challenge session Sham alcohol: non-alcoholic placebo alcohol Session3:placebo naltrexone and placebo (non-alcoholic) alcohol placebo: placebo pills Sham alcohol: non-alcoholic placebo alcohol Session4: alcohol and active naltrexone Naltrexone: 50 mg/day for two days prior to the alcohol challenge session alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice.</description>
        </group>
        <group group_id="P4">
          <title>Placebo-Sham; Placebo-Alc; Ntx-Alc; Ntx-Sham</title>
          <description>Session1: placebo naltrexone and placebo (non-alcoholic) alcohol placebo: placebo pills Sham alcohol: non-alcoholic placebo alcohol Session2: placebo naltrexone and alcohol placebo: placebo pills alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice.
Session3: alcohol and active naltrexone Naltrexone: 50 mg/day for two days prior to the alcohol challenge session alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice.
Session4: &quot;sham&quot; alcohol and active naltrexone Naltrexone: 50 mg/day for two days prior to the alcohol challenge session Sham alcohol: non-alcoholic placebo alcohol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Session1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Session2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Session3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Session4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study Population</title>
          <description>all participants in the cross over study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.5" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol use</title>
          <description>The average number of standard drinks per week prior to the trial.</description>
          <units>total number of drinks in the week prior</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.2" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Biphasic Alcohol Effects Scale - Stimulation</title>
        <description>Change from baseline to peak for the feeling of stimulation after alcohol ingestion
Biphasic Alcohol Effects Scale - Stimulation: sum of 7 items each rated on 11 point Likert scale (0=not at all, 10=extremely). Minimum=0, maximum=70, higher scores=worse outcome.</description>
        <time_frame>During challenge sessions</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ALC and NAL</title>
            <description>alcohol and active naltrexone
Naltrexone: 50 mg/day for two days prior to the alcohol challenge session
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice.</description>
          </group>
          <group group_id="O2">
            <title>Placebo ALC and NAL</title>
            <description>&quot;sham&quot; alcohol and active naltrexone
Naltrexone: 50 mg/day for two days prior to the alcohol challenge session
Sham alcohol: non-alcoholic placebo alcohol</description>
          </group>
          <group group_id="O3">
            <title>Placebo Pill and ALC</title>
            <description>placebo naltrexone and alcohol
placebo: placebo pills
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Pill and Placebo ALC</title>
            <description>placebo naltrexone and placebo (non-alcoholic) alcohol
placebo: placebo pills
Sham alcohol: non-alcoholic placebo alcohol</description>
          </group>
        </group_list>
        <measure>
          <title>Biphasic Alcohol Effects Scale - Stimulation</title>
          <description>Change from baseline to peak for the feeling of stimulation after alcohol ingestion
Biphasic Alcohol Effects Scale - Stimulation: sum of 7 items each rated on 11 point Likert scale (0=not at all, 10=extremely). Minimum=0, maximum=70, higher scores=worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="10.1"/>
                    <measurement group_id="O2" value="3.9" spread="5.1"/>
                    <measurement group_id="O3" value="8.7" spread="7.6"/>
                    <measurement group_id="O4" value="3.2" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Profile of Mood States - Vigor</title>
        <description>Change from baseline to peak for the amount of Vigor experienced after alcohol ingestion
Profile of Mood States - Vigor: sum of 6 items each rated on 5 point Likert scale (0: not at all, 4: extremely). Minimum=0, maximum=20, higher scores = better outcome</description>
        <time_frame>during the challenge session</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ALC and NAL</title>
            <description>alcohol and active naltrexone
Naltrexone: 50 mg/day for two days prior to the alcohol challenge session
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice.</description>
          </group>
          <group group_id="O2">
            <title>Placebo ALC and NAL</title>
            <description>&quot;sham&quot; alcohol and active naltrexone
Naltrexone: 50 mg/day for two days prior to the alcohol challenge session
Sham alcohol: non-alcoholic placebo alcohol</description>
          </group>
          <group group_id="O3">
            <title>Placebo Pill and ALC</title>
            <description>placebo naltrexone and alcohol
placebo: placebo pills
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Pill and Placebo ALC</title>
            <description>placebo naltrexone and placebo (non-alcoholic) alcohol
placebo: placebo pills
Sham alcohol: non-alcoholic placebo alcohol</description>
          </group>
        </group_list>
        <measure>
          <title>Profile of Mood States - Vigor</title>
          <description>Change from baseline to peak for the amount of Vigor experienced after alcohol ingestion
Profile of Mood States - Vigor: sum of 6 items each rated on 5 point Likert scale (0: not at all, 4: extremely). Minimum=0, maximum=20, higher scores = better outcome</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2.5"/>
                    <measurement group_id="O2" value="1.1" spread="1.2"/>
                    <measurement group_id="O3" value="1.8" spread="1.4"/>
                    <measurement group_id="O4" value="1.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective High From Alcohol Scale</title>
        <description>Change from baseline to peak for the self reported feeling of being high after drinking
Subjective High from Alcohol Scale: sum of 15 items rated on a 8 point Likert scale (0-7). Minimum=0, maximum=105, higher scores=worse outcomes</description>
        <time_frame>during the alcohol ingestion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ALC and NAL</title>
            <description>alcohol and active naltrexone
Naltrexone: 50 mg/day for two days prior to the alcohol challenge session
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice.</description>
          </group>
          <group group_id="O2">
            <title>Placebo ALC and NAL</title>
            <description>&quot;sham&quot; alcohol and active naltrexone
Naltrexone: 50 mg/day for two days prior to the alcohol challenge session
Sham alcohol: non-alcoholic placebo alcohol</description>
          </group>
          <group group_id="O3">
            <title>Placebo Pill and ALC</title>
            <description>placebo naltrexone and alcohol
placebo: placebo pills
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Pill and Placebo ALC</title>
            <description>placebo naltrexone and placebo (non-alcoholic) alcohol
placebo: placebo pills
Sham alcohol: non-alcoholic placebo alcohol</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective High From Alcohol Scale</title>
          <description>Change from baseline to peak for the self reported feeling of being high after drinking
Subjective High from Alcohol Scale: sum of 15 items rated on a 8 point Likert scale (0-7). Minimum=0, maximum=105, higher scores=worse outcomes</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" spread="17.2"/>
                    <measurement group_id="O2" value="4.5" spread="5.4"/>
                    <measurement group_id="O3" value="14.7" spread="13.1"/>
                    <measurement group_id="O4" value="2.7" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biphasic Alcohol Effects Scale - Sedation</title>
        <description>Change from baseline to peak of the amount of sedation post ingestion of alcohol
Biphasic alcohol effects scale - Sedation: sum of 7 items rated on 11 point Likert scale (0=not at all, 10=extremely). Minimum=0, maximum=70, lower scores=worse outcomes</description>
        <time_frame>During the challenge session</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ALC and NAL</title>
            <description>alcohol and active naltrexone
Naltrexone: 50 mg/day for two days prior to the alcohol challenge session
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice.</description>
          </group>
          <group group_id="O2">
            <title>Placebo ALC and NAL</title>
            <description>&quot;sham&quot; alcohol and active naltrexone
Naltrexone: 50 mg/day for two days prior to the alcohol challenge session
Sham alcohol: non-alcoholic placebo alcohol</description>
          </group>
          <group group_id="O3">
            <title>Placebo Pill and ALC</title>
            <description>placebo naltrexone and alcohol
placebo: placebo pills
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Pill and Placebo ALC</title>
            <description>placebo naltrexone and placebo (non-alcoholic) alcohol
placebo: placebo pills
Sham alcohol: non-alcoholic placebo alcohol</description>
          </group>
        </group_list>
        <measure>
          <title>Biphasic Alcohol Effects Scale - Sedation</title>
          <description>Change from baseline to peak of the amount of sedation post ingestion of alcohol
Biphasic alcohol effects scale - Sedation: sum of 7 items rated on 11 point Likert scale (0=not at all, 10=extremely). Minimum=0, maximum=70, lower scores=worse outcomes</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="13.7"/>
                    <measurement group_id="O2" value="13.4" spread="16.1"/>
                    <measurement group_id="O3" value="15.9" spread="15.8"/>
                    <measurement group_id="O4" value="15.4" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Profile of Mood States - Fatigue Scale</title>
        <description>Change from baseline to peak of the degree of fatigue experienced after alcohol ingestion
Profile of Mood States - Fatigue scale: sum of 5 items rated on 5-point Likert scale (0=not at all, 4=extremely). Minimum=0, maximum=20, higher score=worse outcome</description>
        <time_frame>During the challenge session</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ALC and NAL</title>
            <description>alcohol and active naltrexone
Naltrexone: 50 mg/day for two days prior to the alcohol challenge session
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice.</description>
          </group>
          <group group_id="O2">
            <title>Placebo ALC and NAL</title>
            <description>&quot;sham&quot; alcohol and active naltrexone
Naltrexone: 50 mg/day for two days prior to the alcohol challenge session
Sham alcohol: non-alcoholic placebo alcohol</description>
          </group>
          <group group_id="O3">
            <title>Placebo Pill and ALC</title>
            <description>placebo naltrexone and alcohol
placebo: placebo pills
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Pill and Placebo ALC</title>
            <description>placebo naltrexone and placebo (non-alcoholic) alcohol
placebo: placebo pills
Sham alcohol: non-alcoholic placebo alcohol</description>
          </group>
        </group_list>
        <measure>
          <title>Profile of Mood States - Fatigue Scale</title>
          <description>Change from baseline to peak of the degree of fatigue experienced after alcohol ingestion
Profile of Mood States - Fatigue scale: sum of 5 items rated on 5-point Likert scale (0=not at all, 4=extremely). Minimum=0, maximum=20, higher score=worse outcome</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="2.1"/>
                    <measurement group_id="O2" value="1.6" spread="1.4"/>
                    <measurement group_id="O3" value="2.0" spread="1.6"/>
                    <measurement group_id="O4" value="1.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored during each session which typically occurred over 3 hours.</time_frame>
      <desc>We assessed for any adverse event reported related to the medication taken prior to the session or the alcohol during the session.</desc>
      <group_list>
        <group group_id="E1">
          <title>ALC and NAL</title>
          <description>alcohol and active naltrexone
Naltrexone: 50 mg/day for two days prior to the alcohol challenge session
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice.</description>
        </group>
        <group group_id="E2">
          <title>Placebo ALC and NAL</title>
          <description>&quot;sham&quot; alcohol and active naltrexone
Naltrexone: 50 mg/day for two days prior to the alcohol challenge session
Sham alcohol: non-alcoholic placebo alcohol</description>
        </group>
        <group group_id="E3">
          <title>Placebo Pill and ALC</title>
          <description>placebo naltrexone and alcohol
placebo: placebo pills
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice.</description>
        </group>
        <group group_id="E4">
          <title>Placebo Pill and Placebo ALC</title>
          <description>placebo naltrexone and placebo (non-alcoholic) alcohol
placebo: placebo pills
Sham alcohol: non-alcoholic placebo alcohol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Oslin, MD</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>2158235894</phone>
      <email>oslin@upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

